Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review.

Ther Adv Infect Dis · 2025 · PMC12033615 · PMID 40292087

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

55 In an exploratory analysis of the phase III SCORPIO-SR study, ensitrelvir treatment in the acute COVID-19 phase showed a trend toward risk reduction for PCC symptoms compared with placebo. 56 However, because of the exploratory nature of the results, the effect of ensitrelvir in preventing PCC warrants further investigation.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.